Comparison of oral versus intravenous etoposide in the management of small‐cell lung cancer; A real‐world, population‐based study

Autor: Hatim Karachiwala, Derek Tilley, Omar Abdel‐Rahman, Don Morris

Publikováno v: The Clinical Respiratory Journal, Vol 15, Iss 1, Pp 36-41 (2021)

Abstract Background We looked at the utility of PO versus IV etoposide for first‐line treatment in combination with a platinum agent (cisplatin/carboplatin) for Small‐Cell Lung Cancer (SCLC). Methods Patients with SCLC in Alberta from 2008 to 201

Externí odkaz: https://doaj.org/article/3cc91bd6ef9d4062b772e867b3685218

The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.

Autor: Satbir Singh Thakur, Haocheng Li, Angela M Y Chan, Roxana Tudor, Gilbert Bigras, Don Morris, Emeka K Enwere, Hua Yang

Publikováno v: PLoS ONE, Vol 13, Iss 1, p e0188983 (2018)

Ki67 is a commonly used marker of cancer cell proliferation, and has significant prognostic value in breast cancer. In spite of its clinical importance, assessment of Ki67 remains a challenge, as current manual scoring methods have high inter- and in

Externí odkaz: https://doaj.org/article/790f93625c154c7f8404e5b0eed22367

Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients.

Autor: Roxana Alina Tudor, Adrijana D'Silva, Alain Tremblay, Paul MacEachern, Don Morris, Darren Brenner, Karen Kopciuk, Dafydd Gwyn Bebb

Publikováno v: PLoS ONE, Vol 12, Iss 8, p e0181867 (2017)

Treatment and clinical-outcomes were described in a sub-cohort of non-small-cell lung cancer (NSCLC) patients with disease-progression (PD) after epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) treatment.We retrospectively analyzed a s

Externí odkaz: https://doaj.org/article/43d261c0ebec4c19a14bfbdcf65c9227

Comparison of oral versus intravenous etoposide in the management of small‐cell lung cancer; A real‐world, population‐based study

Autor: Hatim Karachiwala, Derek Tilley, Omar Abdel-Rahman, Don Morris

Publikováno v: The Clinical Respiratory Journal. 15:36-41

Background We looked at the utility of PO versus IV etoposide for first-line treatment in combination with a platinum agent (cisplatin/carboplatin) for Small-Cell Lung Cancer (SCLC). Methods Patients with SCLC in Alberta from 2008 to 2015 were identi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::343f17bc79260aeb2ba7fe3ab801ab71
https://doi.org/10.1111/crj.13266

Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials

Autor: Chun L. Gan, Daniel E. Meyers, Heidi A. I. Grosjean, Aliyah Pabani, Tina Cheng, Toni K. Choueiri, Sumanta K. Pal, Daniel Y.C. Heng, Naveen S. Basappa, Frede Donskov, Michael Sander, Lori Wood, Igor Stukalin, Shaan Dudani, S. Dolter, Siddhartha Goutam, Connor Wells, Jose Gerard Monzon, Benjamin W. Ewanchuk, Don Morris

Publikováno v: Gan, C L, Stukalin, I, Meyers, D E, Dudani, S, Grosjean, H A I, Dolter, S, Ewanchuk, B W, Goutam, S, Sander, M, Wells, C, Pabani, A, Cheng, T, Monzon, J, Morris, D, Basappa, N S, Pal, S K, Wood, L A, Donskov, F, Choueiri, T K & Heng, D Y C 2021, ' Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials ', European Journal of Cancer, vol. 151, pp. 115-125 . https://doi.org/10.1016/j.ejca.2021.04.004

Background: Immuno-oncology (IO)–based therapies have been approved based on randomised clinical trials, yet a significant proportion of real-world patients are not represented in these trials. We sought to compare the outcomes of trial-ineligible

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb68feab4d3e27cdcf4e38239ab4d0c5
https://pure.au.dk/portal/da/publications/outcomes-of-patients-with-solid-tumour-malignancies-treated-with-firstline-immunooncology-agents-who-do-not-meet-eligibility-criteria-for-clinical-trials(049edcae-1ed9-4e12-b16e-97de3ae12c00).html